[1]Yde SS, Sjoegren P, Heje M, et al. Mucosal melanoma: a literature review[J]. Curr Oncol Rep, 2018, 20: 28. doi: 10.1007/s11912-018-0675-0. [2]Chi Z, Li S, Sheng X, et al. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases[J]. BMC cancer, 2011, 11: 85. doi: 10.1186/1471-2407-11-85. [3]D′angelo SP, Larkin J, Sosman JA, et al. Efficacy and safety of nivolumab alone or in combination With ipilimumab in patients with mucosal melanoma: a pooled analysis[J]. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2017, 35: 226-235. [4]Lee YR, Chen M, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor: new modes and prospects[J]. Nat Rev Mol Cell Biol, 2018, 19: 547-562. [5]Cretella D, Digiacomo G, Giovannetti E, et al. PTEN alterations as a potential mechanism for tumor cell escape from PD-1/PD-L1 inhibition[J]. Cancers, 2019, 11: 1318. doi: 10.3390/cancers11091318. [6]Worby CA, Dixon JE. PTEN[J]. Annu Rev Biochem, 2014, 83: 641-669. [7]Yang J, Ren Y, Wang L, et al. PTEN mutation spectrum in breast cancers and breast hyperplasia[J]. J Cancer Res Clin Oncol, 2010, 136: 1303-1311. [8]Nassar KW, Tan AC. The mutational landscape of mucosal melanoma[J]. Semin Cancer Biol, 2020, 61: 139-148. [9]The Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma[J]. Cell, 2015, 161: 1681-1696. [10]Bucheit AD, Chen G, Siroy A, et al. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations[J]. Clin Cancer Res, 2014, 20: 5527-5536. [11]Peng W, Chen JQ, Liu C, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy[J]. Cancer Discov, 2016, 6: 202-216. [12]Hilke FJ, Sinnberg T, Gschwind A, et al. Distinct mutation patterns reveal melanoma subtypes and influence immunotherapy response in advanced melanoma patients[J]. Cancers, 2020, 12: 2359. doi: 10.3390/cancers12092359. |